9 June 2021 in International Journal Of Clinical Practice
Objective Coronavirus disease 2019 (COVID-19) is an emerging, fast-spreading, highly mortal and worldwide infectious disease. The pulmonary system was defined as the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mortality concept of this disease presented with more severe and systemic disease. The present study investigated the relationship between the patient characteristics at the initial hospital administration and fatality in COVID-19 patients. Methods In this retrospective and comparative cohort study, all the 767 hospitalised COVID-19 patients, treated between 18 March and 15 May 2020 in the Covid Clinics of Gulhane Training and Research Hospital in Ankara, Turkey, were evaluated. Results The fatality rate was significantly increased in patients with any comorbid disease except asthma. The initial laboratory test results indicated highly significant differences according to the patient's outcome. A multifactor logistic regression analysis was performed to calculate the adjusted odds ratios for predicting patient outcomes. Being older than 60 years increased the death risk with an adjusted OR of 7.2 (95% CI: 2.23-23.51; P = .001). The presence of a cancer and the extended duration of intensive care unit treatment were other significant risk factors for nonsurvival. Azithromycin treatment was determined as significantly reduced the death ratio in these patients (P = .002). Conclusion It was revealed that being older than 60 years, presence of a cancer and extended duration of ICU treatment were the major risk factors for predicting fatality rate in hospitalised COVID-19 patients.
14 June 2021 in Flora the Journal of Infectious Diseases and Clinical Microbiology
15 March 2022 in Journal of Health Sciences and Medicine
Aim: Coronavirus disease 2019 (COVID-19) is a pandemic with potential life-threatening outcomes. The current study aims to demonstrate the effect of tocilizumab in COVID-19 related cytokine storm. Material and Method: This retrospective cross-sectional study evaluated the patients who received tocilizumab for COVID-19 related cytokine storm between March and August 2020. Demographic, clinical, and laboratory findings were recorded. Computerized tomography (CT) scans, which were performed before tocilizumab infusion were scored. The characteristics of the patients who survived versus those who did not survive were assessed. Results: There was a total of 137 patients, 99 (72.3%) male and 38 (27.7%) female, with a median age of 62 years. Eighty-six (62.7%) patients had severe; 51 (37.2%) patients had critical disease course. The mortality rate was 24.1%. Higher mortality rates were present among patients older than 65 years, females, and with comorbid diseases (p=0.02, p=0.031, and p=0.01, respectively). The non-survived group had higher rates of mechanical ventilation (MV) support (85.2%) and admission to the intensive care unit (58.8%) (p
26 August 2021 in Akademik Gastroenteroloji Dergisi
Giriş ve Amaç: COVID-19’da karaciğer hasarının ana mekanizmasının, şiddetli akut solunum sendromu koronavirüs-2'nin safra kanalı hücrelerinde yüksek oranda eksprese edilen anjiyotensin dönüştürücü enzim 2 reseptörüne bağlanması olduğu düşünülmektedir. Bu çalışmada COVID-19 tanısı ile yatırılarak takip ve tedavi edilen hastaların, komorbid karaciğer hastalıklarının araştırılması, yatış gününde anormal karaciğer biyokimyasal test sonuçları sıklığının değerlendirilerek hastalığın seyri ve prognozu ile ilişkisinin araştırılması amaçlandı. Gereç ve Yöntem: COVID-19 tanısı ile yatırılarak tedavi edilen 18 yaşından büyük hastalara ait veriler retrospektif olarak değerlendirildi. Hastaların aspartat aminotransferaz, alanin aminotransferaz, alkalen fosfataz, gama glutamil transferaz, total bilirübin değerleri ile hastanede kalış süreleri, yoğun bakım ünitesi ihtiyacı, mortalite arasındaki ilişki araştırıldı. Bulgular: COVID-19 tanısı revers transkripsiyon polimeraz zincir reaksiyonu ile doğrulanmış 795 hastadan 113’ünde (%14.2) yüksek karaciğer enzim (alanin aminotransferaz ve/veya aspartat aminotransferaz) prevalansı saptandı. COVID-19’lu olgularda yüksek alanin aminotransferaz prevalansı %11.1 iken aspartat aminotransferaz prevalansı ise %9.6 idi. Alanin aminotransferaz yüksekliği en fazla 71 yaş ve üstünde (%17.4), aspartat aminotransferaz yüksekliği ise en fazla 51-70 yaş grubunda (%14.8) bulundu. Alanin aminotransferaz ve/veya aspartat aminotransferaz yüksekliği saptanan ve saptanmayan hastalar arasında, hastalığın seyri, hastanede ve yoğun bakımda yatış süresi ve mortalite açısından anlamlı bir fark tespit edilmedi. Ayrıca, aspartat aminotransferaz ve alanin aminotransferaz yüksekliğinin sağ kalım zamanında anlamlı bir fark oluşturmadığı saptandı. Sonuç: COVID-19 hastalarında anormal karaciğer fonksiyon testleri tespit edilebilir. Ancak bunun sebepleri ve prognoza etkileri konusunda yeterli bilgiye sahip olmak için daha geniş popülasyonu içeren prospektif çalışmalara ihtiyaç vardır.